搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
15 天
Does Ozempic cause medullary thyroid cancer?
( NewsNation) — Dr. Ken Berry, a licensed family physician, brings up the medication’s risk to developing GLP-1 receptors. He ...
12 天
科学家构建脑类器官模型,为理解人脑发育和人脑疾病打造新平台
因此,尽管体外的脑区间连接模型缺乏体内发育过程中众多参与因素,但这却为他们探索在不同人脑区域之间如何建立靶向性投射连接的调控机制提供了一个清晰、简便的背景,并能打造出来人源性的研究模型。
5 天
Red flag sign in hands and feet 'could signal cancer', says doctor
Thyroid cancer is a relatively rare type of cancer, but it is important to recognise the signs and symptoms of the disease, ...
Daily
2 天
Real-World Analysis of Tirzepatide Reveals Comparable Safety Profile to GLP-1 Receptor Agonists
Italy: A recent analysis of the FDA Adverse Event Reporting System (FAERS) database has provided new insights into the safety ...
WISH-TV on MSN
17 天
Police officer who ran marathons to fight pediatric cancer loses battle to cancer
A Massachusetts police officer and father of four who ran marathons to raise money for cancer research lost his own race ...
ConsumerAffairs
1 天
Weight loss pills vs. injections: Which is right for you?
Weight loss injections are essentially the opposite of pills in terms of pros and cons. They’re generally more effective and ...
Medscape
8 天
Tirzepatide Real-World Safety Profile "Reassuring," So Far
Data from the US FDA's Adverse Event Reporting System on tirzepatide showed adverse events generally consistent with those ...
3 天
A Closer Look at 5 Analyst Recommendations For Exelixis
Analysts have recently evaluated Exelixis and provided 12-month price targets. The average target is $29.4, accompanied by a high estimate of $33.00 and a low estimate of $27.00. This upward trend is ...
News Medical on MSN
9 天
Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes
As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns ...
Targeted Oncology
4 天
In nccRCC, Ipilimumab With Nivolumab Improves Survival vs SOC
A phase 2 trial of ipilimumab plus nivolumab has met its primary end point of 12-month overall survival rate in non-clear ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈